Role of CAR T-Cell Therapy in Relapsed/Refractory ALL – OncLive
OncLive |
Role of CAR T-Cell Therapy in Relapsed/Refractory ALL
OncLive Aaron C. Logan, MD, PhD: It's definitely exciting, but I think this particular generation of CAR T cells does carry a lot of toxicity, and it requires extreme expertise to administer this therapy to patients. I don't think that 10 years from now, this … CAR T-Cell Therapy in ALL: Formidible Challenges Remain … Global Cell Therapy Processing Market to Reach $5.0 Billion By 2022 |
